Ceramidase

Ceramidases are a group of enzymes that catalyze the hydrolysis of ceramide, dihydroceramide, and phytoceramide into sphingosine (SPH), dihydrosphingosine (DHS), and phytosphingosine (PHS), respectively, along with a free fatty acid. Ceramide catabolism is controlled by ceramidases that are pivotal in the pathophysiology of these diseases of altered lipid homeostasis such as Alzheimer’s disease, type 2 diabetes-induced insulin resistance, cancer, and cardiovascular diseases. Ceramidases are classified into the acid, neutral, and alkaline ceramidase subtypes according to the pH optima for their catalytic activity.

Ceramidase Related Products (36):

By Effects:	Inhibitors (25) Agonist (1) Substrate (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-153396

Acid Ceramidase-IN-2	Inhibitor	99.0%
Acid Ceramidase-IN-2 (compound 1) is an acid ceramidase inhibitor with potentially antiproliferative and cytostatic activities. Moreover, human acid ceramidase is overexpressed in prostate cancer cells, indicating potential anti-tumor effect of Acid Ceramidase-IN-2. And Acid Ceramidase-IN-2 hydrolysis can be inhibited by 3 a-ketoamides GT85, GT98 and GT99 inhibits in vitro.

HY-132882

ARN19689	Inhibitor
ARN19689 is a potent, selective, orally active and non-covalent inhibitor of N Acylethanolamine-Hydrolyzing Acid Amidase (NAAA), with an IC₅₀ of 42 nM. ARN19689 is a promising pharmacological tool to be further investigated in the field of inflammatory conditions.

HY-157223

ARN16186	Inhibitor
ARN16186;ARN 16186;ARN-16186

HY-175496

Acid Ceramidase-IN-3	Inhibitor
Acid Ceramidase-IN-3 is a acid ceramidase (aCDase) inhibitor. Acid Ceramidase-IN-3 inhibits the enzymatic activity of aCDase with a pIC ₅₀ of 8.5 in enzymatic assays and 6.8 in A375 melanoma cellular assays. Acid Ceramidase-IN-3 promotes HSC inactivation, as measured by a dose-dependent reduction in COL1A1 and ACTA2. Acid Ceramidase-IN-3 inhibits aCDase activity in HSCs, promotes HSC inactivation and suppresses YAP/TAZ nuclear localization. Acid Ceramidase-IN-3 increases Dynein/Kinesin (NDE1, NDEL1. KIF3B, KIF15) while decreases several proteins involved with signaling pathway (SARM1, RGAP1, PDGF-D,PDGFR-B). Acid Ceramidase-IN-3 can be used for the study of fibrotic diseases.

HY-139062

C6 Urea Ceramide	Inhibitor
C6 Urea Ceramide (Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. C6 Urea Ceramide increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells. C6 Urea Ceramide (5-10 μM) inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but is not toxic to non-cancerous cells. C6 Urea Ceramide decreases total and phosphorylated β-catenin levels in HT-29 and HCT116 cells, and induces colocalization of β-catenin with the 20S proteasome. C6 Urea Ceramide (1.25, 2.5, and 5 mg/kg) reduced tumor growth and increased C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.

HY-173585

C16 Ceramide (d18:1(14Z)/16:0)
C16 Ceramide (Cer) (d18:1(14Z)/16:0) is a sphingosine ceramide composed of long-chain sphingosine (d18:1) and palmitic acid (C16:0). It is one of the key lipid signaling molecules involved in apoptosis signaling. C16 ceramides are particularly involved in cell cycle arrest, cell death, and insulin signaling inhibition.

HY-N15826

RBM1-151	Substrate
RBM1-151, a 1-deoxy derivative and vinilog of RBM14-C12 (HY-150163), as a fluorogenic substrate of Amidases (HY-P2736) (E_x/E_m). RBM1-151 is hydrolyzed by acid ceramidase (AC) ((^appK_m = 7.0 μM; ^appV_max = 99.3 nM/min), N-acylethanolamine-hydrolyzing acid amidase (^appK_m = 0.73 μM; ^appV_max = 0.24 nM/min), and fatty Acid amide hydrolase (FAAH) (^appK_m = 3.6 μM; ^appV_max = 7.6 nM/min) but not by other ceramidases. RBM1-151 is applicable for basic biological studies of lipid amidase function, as well as potential diagnostic/prognostic evaluations of diseases involving dysregulated AC, NAAA, or FAAH (Farber disease, cancer).

HY-173540

C22:1 1-Deoxyceramide (m18:1/22:1)
C22:1 1-Deoxyceramide (m18:1/22:1) (C22:1(13Z) 1-Deoxyceramide) is a deoxyceramide lipid that lacks the 1-hydroxyl group and is a ceramide variant. C22:1 1-Deoxyceramide (m18:1/22:1) has potential neurotoxicity and is involved in mitochondrial stress and cell death signaling. It can be used to study abnormal sphingolipid metabolism and neurodegenerative diseases.

HY-N15841

C25 Ceramide (d18:1/25:0)	Inhibitor
C25 Ceramide (d18:1/25:0) is an endogenous ultra-long-chain ceramide that antagonizes the detrimental effects of long-chain ceramides on insulin sensitivity. C25 Ceramide (d18:1/25:0) is specifically enriched in oxidative skeletal muscle fibers, where it serves dual roles in providing structural support to cell membranes and regulating cellular signaling. By participating in the regulation of lipid homeostasis within muscle fibers, C25 Ceramide (d18:1/25:0) helps maintain normal insulin signaling. C25 Ceramide (d18:1/25:0) is primarily utilized in research concerning metabolic diseases—particularly in mechanistic studies investigating the muscle fiber type-specific aspects of insulin resistance.

HY-163106

W000113414_I13	Agonist
W000113414_I13 is an acid ceramidase (AC) inhibitor. W000113414_I13 exhibits dose-dependent inhibition of AC with an IC₅₀ value of 6.6?μM. W000113414_I13 can be used for the research of cancer.

HY-169834

NAAA-IN-6	Inhibitor
NAAA-IN-6 (Example 43) is a NAAA inhibitor with IC₅₀ values between 0.01-0.1 µM, which can be used in cancer research.

HY-171003

SOBRAC	Inhibitor
SOBRAC is an irreversible inhibitor of acid ceramidase (Ceramidase) with a K_i of 29.7 nM, and it's also a derivative of the acid ceramidase inhibitor SABRAC (HY-165070).

HY-124134

AD-2646	Inhibitor
AD-2646 (LCL102), a ceramide analog, can kill leukemic T cells (EC₅₀: 40 μM). AD-2646 triggers the cleavage of caspase-8, -9 and -3, as well as the caspase substrate PARP. AD-2646 is a ceramidase inhibitor. AD-2646 induces an accumulation of endogenous ceramide owing to perturbed ceramide metabolism.

HY-103592R

ARN14974 (Standard)	Inhibitor
ARN14974 (Standard) is the analytical standard of ARN14974 (HY-103592). This product is intended for research and analytical applications. ARN14974, a benzoxazolone carboxamide, is a potent and systemically active inhibitors of intracellular acid ceramidase (IC₅₀=79 nM).

HY-B0182R

Carmofur (Standard)	Inhibitor
Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).

HY-N15594

Sphingolipid E
Sphingolipid E is a synthetic pseudoceramide sphingolipid similar to type 2 ceramide with a metastable lamellar structure. Sphingolipid E ??can be used as a potential drug carrier to control the penetration of molecules as a lipid component of the intercellular space of the stratum corneum.

Name
Email *

	Sorry, but the email address you supplied was invalid.